| David Matson, MD | |
|
10230 Baltimore St Ne Ste 300, Blaine, MN 55449-4674 | |
| (651) 968-5201 | |
| (651) 968-5903 |
| Full Name | David Matson |
|---|---|
| Gender | Male |
| Speciality | Orthopaedic Surgery - Hand Surgery |
| Location | 10230 Baltimore St Ne Ste 300, Blaine, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982137741 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207XS0106X | Orthopaedic Surgery - Hand Surgery | 74019 (Minnesota) | Primary |
| Entity Name | Summit Orthopedics Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306899463 PECOS PAC ID: 8921900374 Enrollment ID: O20040126000035 |
News Archive
In order to strengthen the response to HIV in Southeast Michigan, AIDS Partnership Michigan and HIV/AIDS Resource Center have merged their organizations. Building on a history of collaboration and excellence, the merger of APM and HARC will ensure the sustainability of comprehensive HIV/AIDS prevention and care in their now 10-county area where 63% of people living with HIV reside.
In this post in BMJ's "Yankee Doodling," Douglas Kamerow, chief scientist at RTI International and an associate editor for the journal, reflects on the possibility of achieving an AIDS-free generation "if somehow we succeeded in getting all HIV positive people in the world identified and under long term treatment."
Protalix BioTherapeutics, Inc. has announced that it has received written notice from the United States Food and Drug Administration (FDA) that it may initiate a Phase III clinical trial in the United States of its lead product candidate, prGCD, a proprietary plant cell expressed recombinant form of human Glucocerebrosidase (GCD), for the treatment of Gaucher Disease, a lysosomal storage disorder in humans.
Agilent Technologies Inc. and the Agilent Foundation today announced that Dr. Thomas Hartung has received an Agilent Thought Leader Award in support of his research for the use of toxicity pathways to predict developmental neurotoxicity. This work could help identify possible contributions of chemicals to disorders such as autism and attention hyperactivity disorders.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David Matson, MD 710 Commerce Dr Ste 200, Woodbury, MN 55125-4925 Ph: () - | David Matson, MD 10230 Baltimore St Ne Ste 300, Blaine, MN 55449-4674 Ph: (651) 968-5201 |
News Archive
In order to strengthen the response to HIV in Southeast Michigan, AIDS Partnership Michigan and HIV/AIDS Resource Center have merged their organizations. Building on a history of collaboration and excellence, the merger of APM and HARC will ensure the sustainability of comprehensive HIV/AIDS prevention and care in their now 10-county area where 63% of people living with HIV reside.
In this post in BMJ's "Yankee Doodling," Douglas Kamerow, chief scientist at RTI International and an associate editor for the journal, reflects on the possibility of achieving an AIDS-free generation "if somehow we succeeded in getting all HIV positive people in the world identified and under long term treatment."
Protalix BioTherapeutics, Inc. has announced that it has received written notice from the United States Food and Drug Administration (FDA) that it may initiate a Phase III clinical trial in the United States of its lead product candidate, prGCD, a proprietary plant cell expressed recombinant form of human Glucocerebrosidase (GCD), for the treatment of Gaucher Disease, a lysosomal storage disorder in humans.
Agilent Technologies Inc. and the Agilent Foundation today announced that Dr. Thomas Hartung has received an Agilent Thought Leader Award in support of his research for the use of toxicity pathways to predict developmental neurotoxicity. This work could help identify possible contributions of chemicals to disorders such as autism and attention hyperactivity disorders.
› Verified 7 days ago
Kevin Paul Sandhu, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 10230 Baltimore St Ne Ste 300, Blaine, MN 55449 Phone: 651-968-5201 Fax: 651-968-5903 |